The Evidence behind Inhibitor Treatment with Recombinant Factor VIIa

Publisher： Karger

E-ISSN： 1424-8840|32|1|13-18

ISSN： 1424-8832

Source： Pathophysiology of Haemostasis and Thrombosis, Vol.32, Iss.1, 2002-05, pp. : 13-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Evidence behind Inhibitor Treatment with Porcine Factor VIII

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 32, Iss. 1, 2002-05 ,pp. : 5-8

Karger

Access to resources Recommend Favorite

Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation

By Gielen-Wijffels S.   Mook W.   Geest S.   Ramsay G.  

Intensive Care Medicine, Vol. 30, Iss. 6, 2004-06 ,pp. : 1232-1234

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of Bleeding in Patients with Platelet Disorders: Is There a Place for Recombinant Factor VIIa?

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 32, Iss. 1, 2002-05 ,pp. : 37-40

Karger

Access to resources Recommend Favorite

Successful use of recombinant factor VIIa for management of severe menorrhagia in an adolescent with an acquired inhibitor of human thrombin

By  

ACTA PAEDIATRICA, Vol. 93, Iss. 6, 2004-06 ,pp. : 841-843

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors

By Joshi Ashish V.   Stephens Jennifer M.   Munro Vicki   Mathew Prasad   Botteman Marc F.  

Current Medical Research and Opinion, Vol. 22, Iss. 1, 2006-01 ,pp. : 23-31

Informa Healthcare

Access to resources Recommend Favorite